Pharmacogenetics of treatments for inflammatory bowel disease

References

• Mahid SS, Minor KS, Soto RE, et al. Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin Proc. 2006;81(11):1462–1471.
   PubMed Web of Science ®Google Scholar
• Sakamoto N, Kono S, Wakai K, et al. Dietary risk factors for inflammatory bowel disease: a multicenter case-control study in Japan. Inflamm Bowel Dis. 2005;11(2):154–163.
   PubMed Web of Science ®Google Scholar
• Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491(7422):119–124.
   PubMed Web of Science ®Google Scholar
• Liu JZ, van Sommeren S, Huang H, et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet. 2015;47(9):979–986.
   PubMed Web of Science ®Google Scholar
• Franke A, McGovern DP, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn’s disease susceptibility loci. Nat Genet. 2010;42(12):1118–1125.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG clinical guideline: management of Crohn’s disease in adults. Am J Gastroenterol. 2018;113(4):481–517.
   PubMed Web of Science ®Google Scholar
• Lazzerini M, Martelossi S, Magazzu G, et al. Effect of thalidomide on clinical remission in children and adolescents with refractory Crohn disease: a randomized clinical trial. JAMA. 2013;310(20):2164–2173.
   PubMed Web of Science ®Google Scholar
• Lazzerini M, Martelossi S, Magazzu G, et al. Effect of thalidomide on clinical remission in children and adolescents with ulcerative colitis refractory to other immunosuppressives: pilot randomized clinical trial. Inflamm Bowel Dis. 2015;21(8):1739–1749.
   PubMed Web of Science ®Google Scholar
• Rousseaux C, Lefebvre B, Dubuquoy L, et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med. 2005;201(8):1205–1215.
   PubMed Web of Science ®Google Scholar
• Dubuquoy L, Jansson EA, Deeb S, et al. Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis. Gastroenterology. 2003;124(5):1265–1276.
   PubMed Web of Science ®Google Scholar
• Yamamoto-Furusho JK, Jacintez-Cazares M, Furuzawa-Carballeda J, et al. Peroxisome proliferator-activated receptors family is involved in the response to treatment and mild clinical course in patients with ulcerative colitis. Dis Markers. 2014;2014:932530.
   PubMedGoogle Scholar
• Yamamoto-Furusho JK, Penaloza-Coronel A, Sanchez-Munoz F, et al. Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) expression is downregulated in patients with active ulcerative colitis. Inflamm Bowel Dis. 2011;17(2):680–681.
   PubMed Web of Science ®Google Scholar
• Stocco G, Cuzzoni E, De Iudicibus S, et al. Thiopurine metabolites variations during co-treatment with aminosalicylates for inflammatory bowel disease: effect of N-acetyl transferase polymorphisms. World J Gastroenterol. 2015;21(12):3571–3578.
   PubMed Web of Science ®Google Scholar
• Patel H, Barr A, Jeejeebhoy KN. Renal effects of long-term treatment with 5-aminosalicylic acid. Can J Gastroenterol. 2009;23(3):170–176.
   PubMed Web of Science ®Google Scholar
• Heap GA, So K, Weedon M, et al. Clinical features and HLA association of 5-aminosalicylate (5-ASA)-induced nephrotoxicity in inflammatory bowel disease. J Crohns Colitis. 2016;10(2):149–158.
   PubMed Web of Science ®Google Scholar
• Munkholm P, Langholz E, Davidsen M, et al. Frequency of glucocorticoid resistance and dependency in Crohn’s disease. Gut. 1994;35(3):360–362.
   PubMed Web of Science ®Google Scholar
• Tung J, Loftus EV Jr., Freese DK, et al. A population-based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn’s disease and ulcerative colitis. Inflamm Bowel Dis. 2006;12(12):1093–1100.
   PubMed Web of Science ®Google Scholar
• Curkovic I, Egbring M, Kullak-Ublick GA. Risks of inflammatory bowel disease treatment with glucocorticosteroids and aminosalicylates. Dig Dis. 2013;31(3–4):368–373.
   PubMed Web of Science ®Google Scholar
• De Iudicibus S, Franca R, Martelossi S, et al. Molecular mechanism of glucocorticoid resistance in inflammatory bowel disease. World J Gastroenterol. 2011;17(9):1095–1108.
   PubMed Web of Science ®Google Scholar
• van Rossum EF, Koper JW, van den Beld AW, et al. Identification of the BclI polymorphism in the glucocorticoid receptor gene: association with sensitivity to glucocorticoids in vivo and body mass index. Clin Endocrinol (Oxf). 2003;59(5):585–592.
   PubMed Web of Science ®Google Scholar
• De Iudicibus S, Stocco G, Martelossi S, et al. Association of BclI polymorphism of the glucocorticoid receptor gene locus with response to glucocorticoids in inflammatory bowel disease. Gut. 2007;56(9):1319–1320.
   PubMed Web of Science ®Google Scholar
• Russcher H, Smit P, van den Akker EL, et al. Two polymorphisms in the glucocorticoid receptor gene directly affect glucocorticoid-regulated gene expression. J Clin Endocrinol Metab. 2005;90(10):5804–5810.
   PubMed Web of Science ®Google Scholar
• van Rossum EF, Koper JW, Huizenga NA, et al. A polymorphism in the glucocorticoid receptor gene, which decreases sensitivity to glucocorticoids in vivo, is associated with low insulin and cholesterol levels. Diabetes. 2002;51(10):3128–3134.
   PubMed Web of Science ®Google Scholar
• van den Akker EL, Russcher H, van Rossum EF, et al. Glucocorticoid receptor polymorphism affects transrepression but not transactivation. J Clin Endocrinol Metab. 2006;91(7):2800–2803.
   PubMed Web of Science ®Google Scholar
• Huizenga NA, Koper JW, De Lange P, et al. A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo. J Clin Endocrinol Metab. 1998;83(1):144–151.
   PubMed Web of Science ®Google Scholar
• Mwinyi J, Wenger C, Eloranta JJ, et al. Glucocorticoid receptor gene haplotype structure and steroid therapy outcome in IBD patients. World J Gastroenterol. 2010;16(31):3888–3896.
   PubMed Web of Science ®Google Scholar
• Chen HL, Li LR. Glucocorticoid receptor gene polymorphisms and glucocorticoid resistance in inflammatory bowel disease: a meta-analysis. Dig Dis Sci. 2012;57(12):3065–3075.
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Adcock IM. Glucocorticoid resistance in inflammatory diseases. Lancet. 2009;373(9678):1905–1917.
   PubMed Web of Science ®Google Scholar
• Miller AH, Pariante CM, Pearce BD. Effects of cytokines on glucocorticoid receptor expression and function. Glucocorticoid resistance and relevance to depression. Adv Exp Med Biol. 1999;461:107–116.
   PubMed Web of Science ®Google Scholar
• Franchimont D, Martens H, Hagelstein MT, et al. Tumor necrosis factor alpha decreases, and interleukin-10 increases, the sensitivity of human monocytes to dexamethasone: potential regulation of the glucocorticoid receptor. J Clin Endocrinol Metab. 1999;84(8):2834–2839.
   PubMed Web of Science ®Google Scholar
• Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011;474(7351):307–317.
   PubMed Web of Science ®Google Scholar
• Elahi MM, Asotra K, Matata BM, et al. Tumor necrosis factor alpha −308 gene locus promoter polymorphism: an analysis of association with health and disease. Biochim Biophys Acta. 2009;1792(3):163–172.
   PubMed Web of Science ®Google Scholar
• Louis E, Peeters M, Franchimont D, et al. Tumour necrosis factor (TNF) gene polymorphism in Crohn’s disease (CD): influence on disease behaviour? Clin Exp Immunol. 2000;119(1):64–68.
   PubMed Web of Science ®Google Scholar
• Cucchiara S, Latiano A, Palmieri O, et al. Polymorphisms of tumor necrosis factor-alpha but not MDR1 influence response to medical therapy in pediatric-onset inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;44(2):171–179.
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol Rev. 2018;281(1):8–27.
   PubMed Web of Science ®Google Scholar
• Hall SK, Perregaux DG, Gabel CA, et al. Correlation of polymorphic variation in the promoter region of the interleukin-1 beta gene with secretion of interleukin-1 beta protein. Arthritis Rheum. 2004;50(6):1976–1983.
   PubMedGoogle Scholar
• Pociot F, Molvig J, Wogensen L, et al. A TaqI polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro. Eur J Clin Invest. 1992;22(6):396–402.
   PubMed Web of Science ®Google Scholar
• De Iudicibus S, Stocco G, Martelossi S, et al. Genetic predictors of glucocorticoid response in pediatric patients with inflammatory bowel diseases. J Clin Gastroenterol. 2011;45(1):e1–7.
   PubMed Web of Science ®Google Scholar
• Cerretti DP, Kozlosky CJ, Mosley B, et al. Molecular cloning of the interleukin-1 beta converting enzyme. Science. 1992;256(5053):97–100.
   PubMed Web of Science ®Google Scholar
• Thornberry NA, Bull HG, Calaycay JR, et al. A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature. 1992;356(6372):768–774.
   PubMed Web of Science ®Google Scholar
• Wolking S, Schaeffeler E, Lerche H, et al. Impact of genetic polymorphisms of ABCB1 (MDR1, P-glycoprotein) on drug disposition and potential clinical implications: update of the literature. Clin Pharmacokinet. 2015;54(7):709–735.
   PubMed Web of Science ®Google Scholar
• Palmieri O, Latiano A, Valvano R, et al. Multidrug resistance 1 gene polymorphisms are not associated with inflammatory bowel disease and response to therapy in Italian patients. Aliment Pharmacol Ther. 2005;22(11–12):1129–1138.
   PubMed Web of Science ®Google Scholar
• Krupoves A, Mack D, Seidman E, et al. Associations between variants in the ABCB1 (MDR1) gene and corticosteroid dependence in children with Crohn’s disease. Inflamm Bowel Dis. 2011;17(11):2308–2317.
   PubMed Web of Science ®Google Scholar
• Wei JW, Huang K, Yang C, et al. Non-coding RNAs as regulators in epigenetics (Review). Oncol Rep. 2017;37(1):3–9.
   PubMed Web of Science ®Google Scholar
• Zhang X, Biagini Myers JM, Yadagiri VK, et al. Nasal DNA methylation differentiates corticosteroid treatment response in pediatric asthma: a pilot study. PLoS One. 2017;12(10):e0186150.
   PubMed Web of Science ®Google Scholar
• Bachmann PS, Piazza RG, Janes ME, et al. Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition. Blood. 2010;116(16):3013–3022.
   PubMed Web of Science ®Google Scholar
• Tessel MA, Benham AL, Krett NL, et al. Role for microRNAs in regulating glucocorticoid response and resistance in multiple myeloma. Horm Cancer. 2011;2(3):182–189.
   PubMedGoogle Scholar
• Tahara T, Shibata T, Nakamura M, et al. Promoter methylation of protease-activated receptor (PAR2) is associated with severe clinical phenotypes of ulcerative colitis (UC). Clin Exp Med. 2009;9(2):125–130.
   PubMed Web of Science ®Google Scholar
• De Iudicibus S, Lucafo M, Martelossi S, et al. MicroRNAs as tools to predict glucocorticoid response in inflammatory bowel diseases. World J Gastroenterol. 2013;19(44):7947–7954.
   PubMed Web of Science ®Google Scholar
• Lucafo' M, Stankovic B, Kotur N, et al. Pharmacotranscriptomic biomarkers in glucocorticoid treatment of pediatric inflammatory bowel disease. Curr Med Chem. 2018;25(24):2855–2871.
   PubMed Web of Science ®Google Scholar
• Lucafo' M, De Iudicibus S, Di Silvestre A, et al. Long noncoding RNA GAS5: a novel marker involved in glucocorticoid response. Curr Mol Med. 2015;15(1):94–99.
   PubMed Web of Science ®Google Scholar
• Lucafo' M, Bravin V, Tommasini A, et al. Differential expression of GAS5 in rapamycin-induced reversion of glucocorticoid resistance. Clin Exp Pharmacol Physiol. 2016;43(6):602–605.
   PubMed Web of Science ®Google Scholar
• Lucafo' M, Di Silvestre A, Romano M, et al. Role of the long non-coding RNA growth arrest-specific 5 in glucocorticoid response in children with inflammatory bowel disease. Basic Clin Pharmacol Toxicol. 2018;122(1):87–93.
   PubMed Web of Science ®Google Scholar
• Heier CR, Fiorillo AA, Chaisson E, et al. Identification of pathway-specific serum biomarkers of response to glucocorticoid and infliximab treatment in children with inflammatory bowel disease. Clin Transl Gastroenterol. 2016;7(9):e192.
   PubMedGoogle Scholar
• De Iudicibus S, Lucafo' M, Vitulo N, et al. High-throughput sequencing of microRNAs in glucocorticoid sensitive paediatric inflammatory bowel disease patients. Int J Mol Sci. 2018;19:(5).
   Web of Science ®Google Scholar
• Roberts RL, Barclay ML. Update on thiopurine pharmacogenetics in inflammatory bowel disease. Pharmacogenomics. 2015;16(8):891–903.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Rychlewski J, Chrzanowska M, et al. Mechanism of activation of an immunosuppressive drug: azathioprine. Quantum chemical study on the reaction of azathioprine with cysteine. J Am Chem Soc. 2001;123(26):6404–6409.
   PubMed Web of Science ®Google Scholar
• Stocco G, Pelin M, Franca R, et al. Pharmacogenetics of azathioprine in inflammatory bowel disease: a role for glutathione-S-transferase? World J Gastroenterol. 2014;20(13):3534–3541.
   PubMed Web of Science ®Google Scholar
• Peng XX, Shi Z, Damaraju VL, et al. Up-regulation of MRP4 and down-regulation of influx transporters in human leukemic cells with acquired resistance to 6-mercaptopurine. Leuk Res. 2008;32(5):799–809.
   PubMed Web of Science ®Google Scholar
• Fotoohi AK, Lindqvist M, Peterson C, et al. Involvement of the concentrative nucleoside transporter 3 and equilibrative nucleoside transporter 2 in the resistance of T-lymphoblastic cell lines to thiopurines. Biochem Biophys Res Commun. 2006;343(1):208–215.
   PubMed Web of Science ®Google Scholar
• Zaza G, Cheok M, Krynetskaia N, et al. Thiopurine pathway. Pharmacogenet Genomics. 2010;20(9):573–574.
   PubMed Web of Science ®Google Scholar
• Somerville L, Krynetski EY, Krynetskaia NF, et al. Structure and dynamics of thioguanine-modified duplex DNA. J Biol Chem. 2003;278(2):1005–1011.
   PubMed Web of Science ®Google Scholar
• Karim H, Ghalali A, Lafolie P, et al. Differential role of thiopurine methyltransferase in the cytotoxic effects of 6-mercaptopurine and 6-thioguanine on human leukemia cells. Biochem Biophys Res Commun. 2013;437(2):280–286.
   PubMed Web of Science ®Google Scholar
• Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest. 2003;111(8):1133–1145.
   PubMed Web of Science ®Google Scholar
• Sandborn W, Sutherland L, Pearson D, et al. Azathioprine or 6-mercaptopurine for inducing remission of Crohn’s disease. Cochrane Database Syst Rev. 2000;89(21):923.
   Google Scholar
• Mantzaris GJ, Sfakianakis M, Archavlis E, et al. A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis. Am J Gastroenterol. 2004;99(6):1122–1128.
   PubMed Web of Science ®Google Scholar
• Moon W, Loftus EV Jr. Review article: recent advances in pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2016;43(8):863–883.
   PubMed Web of Science ®Google Scholar
• Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet. 1980;32(5):651–662.
   PubMed Web of Science ®Google Scholar
• Ansari A, Hassan C, Duley J, et al. Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther. 2002;16(10):1743–1750.
   PubMed Web of Science ®Google Scholar
• Appell ML, Berg J, Duley J, et al. Nomenclature for alleles of the thiopurine methyltransferase gene. Pharmacogenet Genomics. 2013;23(4):242–248.
   PubMed Web of Science ®Google Scholar
• McLeod HL, Krynetski EY, Relling MV, et al. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia. 2000;14(4):567–572.
   PubMed Web of Science ®Google Scholar
• Relling MV, Schwab M, Whirl-Carrillo M et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update. Clin Pharmacol Ther. 2018;Nov 17. doi:10.1002/cpt.1304. [Epub ahead of print]
   PubMedGoogle Scholar
• Sanderson JD. TPMT testing before starting azathioprine or mercaptopurine: surely just do it? Gastroenterology. 2015;149(4):850–853.
   PubMed Web of Science ®Google Scholar
• Coenen MJ, de Jong DJ, van Marrewijk CJ, et al. Identification of patients with variants in TPMT and dose reduction reduces hematologic events during thiopurine treatment of inflammatory bowel disease. Gastroenterology. 2015;149(4):907–17 e7.
   PubMed Web of Science ®Google Scholar
• Liu C, Yang W, Pei D, et al. Genomewide approach validates thiopurine methyltransferase activity is a monogenic pharmacogenomic trait. Clin Pharmacol Ther. 2017;101(3):373–381.
   PubMed Web of Science ®Google Scholar
• Stocco G, Martelossi S, Arrigo S, et al. Multicentric case-control study on azathioprine dose and pharmacokinetics in early-onset pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2017;23(4):628–634.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn’s disease and severe myelosuppression during azathioprine therapy. Gastroenterology. 2000;118(6):1025–1030.
   PubMed Web of Science ®Google Scholar
• Collie-Duguid ES, Pritchard SC, Powrie RH, et al. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics. 1999;9(1):37–42.
   PubMedGoogle Scholar
• Yang JJ, Landier W, Yang W, et al. Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia. J Clin Oncol. 2015;33(11):1235–1242.
   PubMed Web of Science ®Google Scholar
• Yang SK, Hong M, Baek J, et al. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat Genet. 2014;46(9):1017–1020.
   PubMed Web of Science ®Google Scholar
• Moriyama T, Nishii R, Perez-Andreu V, et al. NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. Nat Genet. 2016;48(4):367–373.
   PubMed Web of Science ®Google Scholar
• Moriyama T, Yang YL, Nishii R, et al. Novel variants in NUDT15 and thiopurine intolerance in children with acute lymphoblastic leukemia from diverse ancestry. Blood. 2017;130(10):1209–1212.
   PubMed Web of Science ®Google Scholar
• Walker G, Harrison J, Voskuil M, et al. OP035 NUDT15 variants contribute to thiopurine-induced myelosuppression in European populations. J Crohns Colitis. 2018;12(S1):S025–S026.
   Google Scholar
• Kakuta Y, Kawai Y, Okamoto D, et al. NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study. J Gastroenterol. 2018;53(9):1065-1078.
   Web of Science ®Google Scholar
• Sumi S, Marinaki AM, Arenas M, et al. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. Hum Genet. 2002;111(4–5):360–367.
   PubMed Web of Science ®Google Scholar
• Marinaki AM, Ansari A, Duley JA, et al. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics. 2004;14(3):181–187.
   PubMedGoogle Scholar
• Odahara S, Uchiyama K, Kubota T, et al. A prospective study evaluating metabolic capacity of thiopurine and associated adverse reactions in Japanese patients with Inflammatory Bowel Disease (IBD). PLoS One. 2015;10(9):e0137798.
   PubMed Web of Science ®Google Scholar
• Citterio-Quentin A, Moulsma M, Gustin MP, et al. ITPA activity in children treated by azathioprine: relationship to the occurrence of adverse drug reactions and inflammatory response. Basic Clin Pharmacol Toxicol. 2018;122(6):588–595.
   PubMed Web of Science ®Google Scholar
• Heap GA, Weedon MN, Bewshea CM, et al. HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nat Genet. 2014;46(10):1131–1134.
   PubMed Web of Science ®Google Scholar
• Wilson A, Jansen LE, Rose RV, et al. HLA-DQA1-HLA-DRB1 polymorphism is a major predictor of azathioprine-induced pancreatitis in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2018;47(5):615–620.
   PubMed Web of Science ®Google Scholar
• Eklund BI, Moberg M, Bergquist J, et al. Divergent activities of human glutathione transferases in the bioactivation of azathioprine. Mol Pharmacol. 2006;70(2):747–754.
   PubMed Web of Science ®Google Scholar
• Stocco G, Martelossi S, Barabino A, et al. Glutathione-S-transferase genotypes and the adverse effects of azathioprine in young patients with inflammatory bowel disease. Inflamm Bowel Dis. 2007;13(1):57–64.
   PubMed Web of Science ®Google Scholar
• Stocco G, Cuzzoni E, De Iudicibus S, et al. Deletion of glutathione-s-transferase m1 reduces azathioprine metabolite concentrations in young patients with inflammatory bowel disease. J Clin Gastroenterol. 2014;48(1):43–51.
   PubMed Web of Science ®Google Scholar
• Broekman M, Wong DR, Wanten GJA, et al. The glutathione transferase Mu null genotype leads to lower 6-MMPR levels in patients treated with azathioprine but not with mercaptopurine. Pharmacogenomics J. 2018;18(1):160–166.
   PubMed Web of Science ®Google Scholar
• Ritter B, Modregger J, Paulsson M, et al. PACSIN 2, a novel member of the PACSIN family of cytoplasmic adapter proteins. FEBS Lett. 1999;454(3):356–362.
   PubMed Web of Science ®Google Scholar
• Stocco G, Yang W, Crews KR, et al. PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity. Hum Mol Genet. 2012;21(21):4793–4804.
   PubMed Web of Science ®Google Scholar
• Roberts RL, Wallace MC, Seinen ML, et al. PACSIN2 does not influence thiopurine-related toxicity in patients with inflammatory bowel disease. Am J Gastroenterol. 2014;109(6):925–927.
   PubMed Web of Science ®Google Scholar
• Ban H, Andoh A, Imaeda H, et al. The multidrug-resistance protein 4 polymorphism is a new factor accounting for thiopurine sensitivity in Japanese patients with inflammatory bowel disease. J Gastroenterol. 2010;45(10):1014–1021.
   PubMed Web of Science ®Google Scholar
• Osterman MT, Kundu R, Lichtenstein GR, et al. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology. 2006;130(4):1047–1053.
   PubMed Web of Science ®Google Scholar
• Lim SZ, Chua EW. Revisiting the role of thiopurines in inflammatory bowel disease through pharmacogenomics and use of novel methods for therapeutic drug monitoring. Front Pharmacol. 2018;9:1107.
   PubMed Web of Science ®Google Scholar
• Dubinsky MC, Yang H, Hassard PV, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology. 2002;122(4):904–915.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ. Rational dosing of azathioprine and 6-mercaptopurine. Gut. 2001;48(5):591–592.
   PubMed Web of Science ®Google Scholar
• Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature. 2015;526(7573):343–350.
   PubMed Web of Science ®Google Scholar
• Stocco G, Londero M, Campanozzi A, et al. Usefulness of the measurement of azathioprine metabolites in the assessment of non-adherence. J Crohns Colitis. 2010;4(5):599–602.
   PubMed Web of Science ®Google Scholar
• Friedman AB, Brown SJ, Bampton P, et al. Randomised clinical trial: efficacy, safety and dosage of adjunctive allopurinol in azathioprine/mercaptopurine nonresponders (AAA Study). Aliment Pharmacol Ther. 2018;47(8):1092–1102.
   PubMed Web of Science ®Google Scholar
• Kiszka-Kanowitz M, Theede K, Mertz-Nielsen A. Randomized clinical trial: a pilot study comparing efficacy of low-dose azathioprine and allopurinol to azathioprine on clinical outcomes in inflammatory bowel disease. Scand J Gastroenterol. 2016;51(12):1470–1475.
   PubMed Web of Science ®Google Scholar
• Wu R, Cheng YJ, Zhu LL, et al. Impact of HLA-B*58:01 allele and allopurinol-induced cutaneous adverse drug reactions: evidence from 21 pharmacogenetic studies. Oncotarget. 2016;7(49):81870–81879.
   PubMedGoogle Scholar
• Saito Y, Stamp LK, Caudle KE, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update. Clin Pharmacol Ther. 2016;99(1):36–37.
   PubMed Web of Science ®Google Scholar
• Levin AD, Wildenberg ME, van den Brink GR. Mechanism of action of anti-TNF therapy in inflammatory bowel disease. J Crohns Colitis. 2016;10(8):989–997.
   PubMed Web of Science ®Google Scholar
• Quetglas EG, Mujagic Z, Wigge S, et al. Update on pathogenesis and predictors of response of therapeutic strategies used in inflammatory bowel disease. World J Gastroenterol. 2015;21(44):12519–12543.
   PubMed Web of Science ®Google Scholar
• Billmeier U, Dieterich W, Neurath MF, et al. Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases. World J Gastroenterol. 2016;22(42):9300–9313.
   PubMed Web of Science ®Google Scholar
• Guo Y, Lu N, Bai A. Clinical use and mechanisms of infliximab treatment on inflammatory bowel disease: a recent update. Biomed Res Int. 2013;2013:581631.
   PubMed Web of Science ®Google Scholar
• Naviglio S, Giuffrida P, Stocco G, et al. How to predict response to anti-tumour necrosis factor agents in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2018;12(8):797–810.
   PubMed Web of Science ®Google Scholar
• O’Rielly DD, Roslin NM, Beyene J, et al. TNF-alpha-308 G/A polymorphism and responsiveness to TNF-alpha blockade therapy in moderate to severe rheumatoid arthritis: a systematic review and meta-analysis. Pharmacogenomics J. 2009;9(3):161–167.
   PubMed Web of Science ®Google Scholar
• Netz U, Carter JV, Eichenberger MR, et al. Genetic polymorphisms predict response to anti-tumor necrosis factor treatment in Crohn’s disease. World J Gastroenterol. 2017;23(27):4958–4967.
   PubMed Web of Science ®Google Scholar
• Bank S, Andersen PS, Burisch J, et al. Associations between functional polymorphisms in the NFkappaB signaling pathway and response to anti-TNF treatment in Danish patients with inflammatory bowel disease. Pharmacogenomics J. 2014;14(6):526–534.
   PubMed Web of Science ®Google Scholar
• Fujino S, Andoh A, Bamba S, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut. 2003;52(1):65–70.
   PubMed Web of Science ®Google Scholar
• Zwiers A, Kraal L, van de Pouw Kraan TC, et al. Cutting edge: a variant of the IL-23R gene associated with inflammatory bowel disease induces loss of microRNA regulation and enhanced protein production. J Immunol. 2012;188(4):1573–1577.
   PubMed Web of Science ®Google Scholar
• Jurgens M, Laubender RP, Hartl F, et al. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis. Am J Gastroenterol. 2010;105(8):1811–1819.
   PubMed Web of Science ®Google Scholar
• Koder S, Repnik K, Ferkolj I, et al. Genetic polymorphism in ATG16L1 gene influences the response to adalimumab in Crohn’s disease patients. Pharmacogenomics. 2015;16(3):191–204.
   PubMed Web of Science ®Google Scholar
• Romero-Cara P, Torres-Moreno D, Pedregosa J, et al. A FCGR3A polymorphism predicts anti-drug antibodies in chronic inflammatory bowel disease patients treated with anti-TNF. Int J Med Sci. 2018;15(1):10–15.
   PubMed Web of Science ®Google Scholar
• Moroi R, Endo K, Kinouchi Y, et al. FCGR3A-158 polymorphism influences the biological response to infliximab in Crohn’s disease through affecting the ADCC activity. Immunogenetics. 2013;65(4):265–271.
   PubMed Web of Science ®Google Scholar
• Hlavaty T, Pierik M, Henckaerts L, et al. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn’s disease. Aliment Pharmacol Ther. 2005;22(7):613–626.
   PubMed Web of Science ®Google Scholar
• Li P, Nijhawan D, Budihardjo I, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell. 1997;91(4):479–489.
   PubMed Web of Science ®Google Scholar
• Black RA. Tumor necrosis factor-alpha converting enzyme. Int J Biochem Cell Biol. 2002;34(1):1–5.
   PubMed Web of Science ®Google Scholar
• Dideberg V, Theatre E, Farnir F, et al. The TNF/ADAM 17 system: implication of an ADAM 17 haplotype in the clinical response to infliximab in Crohn’s disease. Pharmacogenet Genomics. 2006;16(10):727–734.
   PubMed Web of Science ®Google Scholar
• Fujioka S, Nakamichi I, Esaki M, et al. Serum microRNA levels in patients with Crohn’s disease during induction therapy by infliximab. J Gastroenterol Hepatol. 2014;29(6):1207–1214.
   PubMed Web of Science ®Google Scholar
• Arijs I, Li K, Toedter G, et al. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut. 2009;58(12):1612–1619.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146(1):85–95.
   PubMed Web of Science ®Google Scholar
• Telesco SE, Brodmerkel C, Zhang H, et al. Gene expression signature for prediction of golimumab response in a phase 2a open-label trial of patients with ulcerative colitis. Gastroenterology. 2018;155(4):1008–1011.
   PubMed Web of Science ®Google Scholar
• Geremia A, Jewell DP. The IL-23/IL-17 pathway in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2012;6(2):223–237.
   PubMed Web of Science ®Google Scholar
• Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease. Nat Genet. 2008;40(8):955–962.
   PubMed Web of Science ®Google Scholar
• MacDonald JK, Nguyen TM, Khanna R, et al. Anti-IL-12/23p40 antibodies for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2016;11:CD007572.
   PubMedGoogle Scholar
• Talamonti M, Botti E, Galluzzo M, et al. Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab. Br J Dermatol. 2013;169(2):458–463.
   PubMed Web of Science ®Google Scholar
• Loft ND, Skov L, Iversen L, et al. Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis. Pharmacogenomics J. 2018;18(3):494–500.
   PubMed Web of Science ®Google Scholar
• Peltekova VD, Wintle RF, Rubin LA, et al. Functional variants of OCTN cation transporter genes are associated with Crohn disease. Nat Genet. 2004;36(5):471–475.
   PubMed Web of Science ®Google Scholar
• Zundler S, Becker E, Weidinger C, et al. Anti-adhesion therapies in inflammatory bowel disease-molecular and clinical aspects. Front Immunol. 2017;8:891.
   PubMed Web of Science ®Google Scholar
• Berends SE, Strik AS, Lowenberg M, et al. Clinical pharmacokinetic and pharmacodynamic considerations in the treatment of ulcerative colitis. Clin Pharmacokinet. 2018:1-23.
   PubMed Web of Science ®Google Scholar
• Majumdar S, Lamothe B, Aggarwal BB. Thalidomide suppresses NF-kappa B activation induced by TNF and H2O2, but not that activated by ceramide, lipopolysaccharides, or phorbol ester. J Immunol. 2002;168(6):2644–2651.
   PubMed Web of Science ®Google Scholar
• Moreira AL, Sampaio EP, Zmuidzinas A, et al. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med. 1993;177(6):1675–1680.
   PubMed Web of Science ®Google Scholar
• Bauditz J, Wedel S, Lochs H. Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn’s disease. Gut. 2002;50(2):196–200.
   PubMed Web of Science ®Google Scholar
• Paravar T, Lee DJ. Thalidomide: mechanisms of action. Int Rev Immunol. 2008;27(3):111–135.
   PubMed Web of Science ®Google Scholar
• Ito T, Ando H, Suzuki T, et al. Identification of a primary target of thalidomide teratogenicity. Science. 2010;327(5971):1345–1350.
   PubMed Web of Science ®Google Scholar
• Bastuji-Garin S, Ochonisky S, Bouche P, et al. Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients. J Invest Dermatol. 2002;119(5):1020–1026.
   PubMed Web of Science ®Google Scholar
• Bramuzzo M, Stocco G, Montico M, et al. Risk factors and outcomes of thalidomide-induced peripheral neuropathy in a pediatric inflammatory bowel disease Cohort. Inflamm Bowel Dis. 2017;23(10):1810–1816.
   PubMed Web of Science ®Google Scholar
• Deeken JF, Cormier T, Price DK, et al. A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform. Pharmacogenomics J. 2010;10(3):191–199.
   PubMed Web of Science ®Google Scholar